Chongqing Taiji Industry(Group) Co.,Ltd: history, ownership, mission, how it works & makes money

From its founding in 1972 to becoming a national TCM export base in Chongqing, Chongqing Taiji Industry Co., Ltd. has built a data-rich trajectory - boasting a workforce of 11,971 employees, a market capitalization near 11.46 billion yuan (Nov 2025) and nearly 300 authorized patents alongside over 1,200 drug approvals that span traditional Chinese and modern medicines; the group's recognized milestones include a national-level postdoctoral workstation (1998), a national enterprise technology center (1999), national intellectual property demonstration status (2016) and a #13 rank in Brand Finance Chinese Pharma 2021, while its operations span Pharmaceutical Industry, Pharmaceutical Commercial, Chinese Herbal Medicine Resources and Service segments with manufacturing capacity such as an annual 2 billion-bottle oral liquid line and a 100 million-bottle syrup line, processing up to 100,000 tons of herbal medicines yearly - yet recent financials show 12.39 billion yuan in 2024 revenue (down 20.72% YoY) and a net profit of 26.65 million yuan in 2024 (down 96.76% YoY), followed by a 1H2025 attributable net income of about 139 million yuan (down ~71.9% YoY), prompting intensified R&D, marketing reforms, operation control and a secured stock-repurchase financing commitment of up to 108 million yuan from China Merchants Bank to support strategic adjustment and growth initiatives.

Chongqing Taiji Industry Co.,Ltd (600129.SS): Intro

• 1972: Company origins-production of TCM formulations and pharmaceutical intermediates.
• 1998: Established a national-level postdoctoral workstation to bolster R&D talent and pipelines.
• 1999: Technology center recognized as a national enterprise technology center, elevating its innovation credentials.
• 2016: Awarded national intellectual property demonstration enterprise, reflecting systematic IP management.
• 2021: Ranked 13th in Brand Finance Chinese Pharma 2021, signaling strong brand equity in China's pharma market.
• March 2022: Approved as Chongqing's first national TCM service export base, advancing internationalization.

• Listed parent: Chongqing Taiji Industry Co.,Ltd (600129.SS) - publicly traded on the SSE.
• Largest shareholder: Chongqing Taiji (Group) Co., Ltd. (state-affiliated industrial group) - controlling stake (majority/near-majority; historically ~30-40% range), plus various institutional and retail shareholders on-exchange.
• Group structure: Multiple subsidiaries for R&D, API & intermediates production, finished-dose manufacturing, distribution, and international trade/exports; vertical integration reduces supply-chain risk and captures margin across value chain.

• Mission: To integrate traditional Chinese medicine heritage with modern pharmaceutical science to improve public health and create sustainable shareholder value.
• Vision: Be a globally respected Chinese pharmaceutical brand advancing TCM modernization and internationalization.
• Core values: Innovation-driven R&D, quality & safety assurance, intellectual property protection, and international market expansion.

• R&D and innovation: National-level postdoctoral workstation and national technology center focus on TCM formula modernization, new chemical entities (where applicable), process optimization and formulation technology. R&D spend historically around 3% of revenue, with projects spanning clinical research, quality standard upgrades and IP filings.
• Manufacturing: Operates multiple GMP-compliant facilities producing APIs, intermediates, finished TCM and modern dosage forms (tablets, capsules, injections, granules). Vertical integration enables internal supply of APIs to finished-product lines.
• Quality and IP: National intellectual property demonstration status reflects active patenting and trademark strategies; quality control adheres to national GMP and pharmacopoeial standards for both TCM and modern drugs.
• Sales & distribution: Multi-channel domestic distribution (provincial distributors, hospital channels, pharmacy chains, online healthcare platforms) plus an export channel anchored by the national TCM service export base designation.
• Internationalization: Leveraging the TCM service export base to expand exports of finished products, proprietary formulations and technical services to Asia, Africa, Europe and Latin America.

• Product sales: Core revenue from finished pharmaceuticals-both TCM specialties and modern drugs-sold to hospitals, pharmacies and retailers. High-volume, low-margin generic-like products sit alongside higher-margin proprietary TCM formulations.
• API & intermediates sales: Supplying in-house and external clients; provides margin diversification and supply control.
• Contract manufacturing & OEM: Toll-manufacturing and private-label production for domestic and overseas partners.
• Export & service revenue: Cross-border sales of finished products and TCM-related services (clinical, regulatory support, technology licensing) amplified after national export base approval.
• IP & licensing: Licensing of proprietary formulations, trademarks and technology where applicable, contributing to higher-margin income streams.

• Product mix: Shifts toward higher-margin proprietary TCM products and specialty formulations improve gross margin.
• R&D productivity: Successful clinical outcomes or approvals for new or upgraded products drive revenue growth and extend patent life/market exclusivity.
• Scale and integration: Vertical integration of API-to-finished-product lowers COGS and stabilizes supply, benefiting EBITDA.
• Regulatory landscape: TCM modernization policies and national support for TCM exports create tailwinds; regulatory compliance costs can raise near-term CAPEX/OPEX.
• Market access: Hospital procurement policies, reimbursement listings (NDRC/NRDL) and inclusion in provincial formularies materially affect sales volumes for specific products.

Chongqing Taiji Industry Co.,Ltd (600129.SS): History

• Public listing: Shanghai Stock Exchange, ticker 600129.SS
• Workforce: 11,971 employees (Dec 2024)
• Market capitalization: ~11.46 billion CNY (Nov 2025)

• Chairman: Mr. Yang Jun (as of March 2025)
• President & General Manager: Mr. Li Hongjian (as of March 2025)
• New non-executive directors: Mr. Liu Haijian and Mr. Li Xiangrong (appointed Jan 2025)
• Major shareholder group: Taiji Group (parent/controlling interest; engages in capital operations and strategic coordination)

• Aug 2025: Taiji Group secured a loan commitment letter from China Merchants Bank - Chongqing Branch for up to 108 million CNY earmarked for stock repurchase, indicating available leverage for capital management and shareholder value initiatives.
• Public market metrics (Nov 2025): market cap ~11.46 billion CNY - a gauge of investor valuation and liquidity for the listed parent.

• Core revenue drivers: production and sale of chemical intermediates, specialty chemicals and pharmaceutical raw materials to domestic and export markets.
• Value-add services: R&D and custom synthesis for industrial customers, providing higher-margin contract manufacturing.
• Capital operations: equity holdings, trading and occasional share repurchase plans funded via bank facilities (e.g., 108 million CNY credit line for repurchases, Aug 2025).

• Mission: supply reliable chemical and pharmaceutical inputs while advancing process efficiency and environmental compliance.
• Strategy highlights: scale manufacturing capacity, expand R&D-driven product mix, optimize capital structure and pursue shareholder-return measures.

Chongqing Taiji Industry Co.,Ltd (600129.SS): Ownership Structure

• Chongqing Taiji Industry Co.,Ltd (600129.SS) is committed to becoming a world-class traditional Chinese medicine (TCM) enterprise, safeguarding human health through its products and services.
• The company emphasizes intelligent manufacturing of modern TCM, while also producing anesthetics and psychiatric drugs to broaden its therapeutic scope and innovation footprint.
• Taiji pursues integration of informatization and industrialization, digitalizing pharmaceutical production and quality control to raise efficiency and traceability.

• Nearly 300 authorized patents.
• Over 1,200 drug approvals in total - including nearly 700 TCM approvals and more than 500 chemical drug approvals.
• Recognized among China's Top 100 Pharmaceutical Companies by the Ministry of Industry and Information Technology (MIIT).
• TCM extraction center passed MIIT technical review for pharmaceutical industry digitalization; awarded MIIT certificate for integration of informatization and industrialization.

• Product portfolio: modernized TCM formulations, prescription and OTC chemical drugs, anesthetics, and psychiatric medicines.
• Manufacturing and intelligent production: revenue from large-scale manufacturing, contract manufacturing, and sales of self-developed brands across domestic and export markets.
• R&D commercialization: leveraging nearly 300 patents and 1,200+ approvals to launch new formulations and sustain lifecycle revenue from established drugs.
• Regulatory and quality-driven premium pricing: MIIT recognitions and digitalized production support market access and price negotiation for clinical and institutional buyers.

• Controlling influence: Chongqing Taiji Group (the Taiji Group parent/major shareholder) holds the controlling stake and sets strategic direction for the listed company.
• Listed vehicle: shares trade on the Shanghai Stock Exchange (600129.SS) with a public free float of institutional and retail investors.
• Governance focus: board and executive management emphasize R&D investment, quality compliance, and expansion of intelligent manufacturing capacity.

Chongqing Taiji Industry Co.,Ltd (600129.SS): Mission and Values

• Primary operating segments: Pharmaceutical Industry, Pharmaceutical Commercial, Chinese Herbal Medicine Resources, Service Industry and Others.
• Listed ticker: 600129.SS (Shanghai Stock Exchange).
• Major shareholder structure: controlled by Chongqing Taiji Group (state/collective-affiliated holding) alongside public institutional and retail shareholders.

• Manufacturing and formulation: produces finished dosage forms (tablets, capsules, syrups, oral liquids, injectables) supplying hospitals, retail pharmacies and distribution channels.
• Commercial distribution: wholesale and retail pharmaceutical trading via the Pharmaceutical Commercial segment, supplying downstream pharmacies and medical institutions.
• Herbal upstream integration: cultivation, procurement, pre-processing, extraction and concentration of Chinese herbal medicines to supply in-house and external formulators.
• Services and logistics: warehousing, third‑party logistics, catering, accommodation, loading/unloading, and ancillary services that monetize existing infrastructure.
• Specialized production: designated producer status for anesthetics and psychiatric drugs in Southwest China - a regulated niche with high entry barriers and stable institutional demand.

• Digestive system & metabolic drugs
• Respiratory system drugs
• Cardiovascular & cerebrovascular drugs
• Anti‑infective agents
• Nervous system drugs (including psychiatric formulations)
• Anti‑tumor and immunomodulatory medicines

• Product sales - finished pharmaceuticals (Rx and OTC) across therapeutic categories sold through hospital procurement, distributors and pharmacies.
• Distribution margins - third‑party wholesale and commercial trade within the Pharmaceutical Commercial segment.
• Contract manufacturing & toll processing - using large syrup/oral liquid capacities and herbal extraction facilities for external clients.
• Herbal raw material sales - monetizing upstream cultivated and pre‑processed herbal feedstock and extracts.
• Service & logistics income - warehousing, catering, accommodation, handling and other service fees from group and external customers.

• Vertical integration from herbal resources to finished dosage forms reduces raw material cost exposure and secures supply chains.
• Large-scale liquid formulation capacity (100M syrups; 2B oral liquids) supports high-volume, low‑margin consumer and institutional products.
• Extraction capability of 100,000 tons/year positions the company as a major processor in China's TCM supply chain.
• Regulatory approvals for anesthetics and psychiatric drugs create high-barrier institutional revenue streams with predictable demand.

• Capacity utilization and product mix drive gross margins: high-volume oral liquids and syrup lines optimize fixed-cost absorption.
• Herbal processing throughput (100,000 t/year) enables internal vertical supply and external toll-processing revenue.
• Commercial segment turnover leverages distribution networks to convert manufacturing output into market share across Southwest China and national channels.

Chongqing Taiji Industry Co.,Ltd (600129.SS): How It Works

• Core business lines: API and chemical drug manufacturing, TCM preparations, health products, and research & development.
• Sales channels: institutional (hospitals and clinics), distribution partners, online and retail terminals.
• Support functions: centralized procurement, quality control, regulatory affairs, and academic promotion to drive prescriptions and market adoption.

• Manufacturing and sale of APIs and finished pharmaceuticals generate the bulk of revenue via B2B contracts and tender wins.
• Proprietary TCM and health supplement lines contribute margin through branded pricing and terminal marketing campaigns.
• R&D-driven new products and secondary product upgrades aim to create higher-margin product mixes and license/royalty opportunities.
• Academic promotion and marketing reforms increase prescription penetration and terminal sales conversion.

• High social inventories of certain products reduced sales recognition and pricing power in 2024, leading to a 20.72% revenue decline to CNY 12.39 billion.
• Significant asset impairment charges and tax compensations for subsidiaries drove net profit down to CNY 26.65 million in 2024 (a 96.76% decline).
• Ongoing market challenges and slower demand resulted in H1 2025 net income attributable to shareholders of ~CNY 139 million, down ~71.90% year-on-year.

• R&D and product pipeline: increased investment in secondary product development and new product research to diversify revenue and improve margins.
• Academic promotion: building a professional academic promotion system to support prescription growth and evidence-based positioning.
• Marketing reforms: strengthening terminal marketing and distributor management to accelerate sell-through and reduce channel inventory.
• Operational control: strict delivery management and tighter operations to improve cash conversion and limit future impairment risk.

• Revenue recovery targets via new product launches and enhanced terminal marketing.
• Margin improvement driven by higher-margin proprietary products and optimized product mix.
• Inventory turnover enhancements to reduce social inventory and release working capital.
• R&D spend allocation toward products with clear commercialization timelines and expected payback.

Chongqing Taiji Industry Co.,Ltd (600129.SS): How It Makes Money

• Core revenue streams: proprietary TCM formulations, cardiovascular & metabolic pharmaceuticals, APIs and intermediates, and contract manufacturing/export services.
• Commercial strategy: strengthen academic promotion, advance professional medical detailing, and expand secondary product lines to capture share in hospital and retail channels.
• Operational focus: tighten delivery controls, optimize production efficiency, and reform marketing to improve terminal conversion rates.

• Internationalization: approval as Chongqing's national TCM export base (Mar 2022) opens structured export channels and service models to overseas markets, expected to lift export revenue contribution.
• Growth drivers: increased R&D pipeline, enhanced academic promotion system, and marketing/terminal reforms aimed at higher sell‑through and margin expansion.